Given that Avadel has publicly stated the jury's decision will not affect the commercial launch or potential of LUMRYZ, it suggests confidence in the product's market introduction and its ability to meet the needs of narcolepsy patients. This could maintain or potentially increase investor confidence in Avadel's stock in the short term, assuming the market perceives the news as a positive affirmation of the company's future revenue prospects.